GoldenGolden
Advanced Search
Rapha Capital Management

Rapha Capital Management

A venture capital firm in Miami that focuses on medicine, healthcare and technology.

Rapha Capital Management is a venture capital firm in Miami that focuses on medicine, healthcare and technology. Founded in Miami, Florida, United States by Kevin Slawin, it invests in series C and convertible notes. Its portfolio companies include Poseida Therapeutics, and AsclepiX Therapeutics. Poseida Therapeutics utilizes best-in-class genome engineering capabilities to develop targeted lifesaving therapeutics. AsclepiX Therapeutics is a biotech company that develops novel therapeutics to revolutionize the treatment of retinal diseases and cancer. As of March 2020, Rapha Capital Management has made two investments. Their most recent investment was on April 22, 2019, when Poseida Therapeutics raised $142M.

Timeline

May 3, 2021
Rapha Capital Management Launches First Fund

I, LP, is solely focused on investment in early-stage life science companies. The fund will focus on securing the investment lead, typically at Series A or just before, in target companies.

Kevin Slawin, MD, the Founder and Managing Partner of Rapha Capital Management, LLC is an oncologic and robotic surgeon, biotech consultant, investor, and founder focusing on disruptive technologies in oncology, T cells and immunotherapy, as well as other breakthrough healthcare technologies.

People

Name
Role
LinkedIn

Kevin Slawin

Founder

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

AsclepiX Therapeutics

Poseida Therapeutics

News

Title
Author
Date
Publisher
Description
FinSMEs
May 3, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Ben Adams
April 16, 2021
FierceBiotech
Life science venture capital firm Rapha Capital Management has launched its first managed venture capital fund with a target raise of $100M and "solely focused" on investment in early-stage life science companies.
FinSMEs
April 7, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Rapha Capital Management, LLC and Ponce Therapeutics, Inc.
February 8, 2021
www.prnewswire.com:443
/PRNewswire/ -- Ponce Therapeutics, Inc. ("Ponce"), a company leveraging the growing scientific knowledge surrounding the aging process to develop anti-aging...

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.